Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Study Overview

Primary Objectives:

Dose Escalation: Part A (SAR439859 monotherapy); Part C (combination of SAR439859 with palbociclib)

  • To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR439859 based on the dose-limiting toxicity (DLT) observance in monotherapy (Part A), and in combination with palbociclib (Part C)

Dose Expansion: Part B (SAR439859 monotherapy); Part D (combination of SAR439859 with palbociclib)

  • To assess antitumor activity by Objective Response Rate (ORR) at the SAR439859 recommended dose in monotherapy (Part B), and in combination with palbociclib (Part D)

Secondary Objectives:

  • Overall safety profile of SAR439859 as monotherapy (Parts A, B), and in combination with palbociclib (Parts C, D)
  • Pharmacokinetic (PK) profile of SAR439859 as monotherapy (Parts A, B), and of SAR439859 in combination with palbociclib (Parts C, D), and of palbociclib in combination with SAR439859 (Parts C, D)
  • Antitumor activity of SAR439859 as monotherapy (Part A), and in combination with palbociclib (Part C) as well as the Clinical Benefit Rate (CBR: Complete Response [CR], Partial Response [PR] and Stable Disease [SD] =24 weeks) in Parts A, B, C, and D
  • ORR and CBR (CR, PR and SD =24 weeks) according to the estrogen receptor 1 (ESR1) gene mutational status (mutant and wild type) at baseline and in treatment
  • Time to first tumor response (CR or PR) in Parts B and D
  • Residual estrogen receptor (ER) availability with [(18)F] Fluoroestradiol Positron Emission Tomography (FES PET) scan (Part A)
  • To assess potential induction/inhibition effect of SAR439859 on CYP3A (Part B)

Study Description

A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

  • ClinicalTrials.gov Identifier: NCT03284957
  • Protocol Number: 17-371
  • Principal Investigator: Jaymin Patel

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000